Study to assess the role of bromocriptine in treatment of diabetes mellitus

Anuj Kumar Pathak, Subodh Kumar, Manish Kumar, Harihar Dikshit


Background: Bromocriptine is a dopamine D2 receptor agonist and a sympatholytic agent used very frequently in treatment of hyperprolactinemia, Parkinsonism and acromegaly. Its quick release formulation has been approved for treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. This study evaluated the antihyperglycemic effect of quick release bromocriptine in alloxan induced diabetic rats.

Methods: 24 albino rats were taken and divided into four groups of six rats in each group. Diabetes was induced in three groups and one group was kept as a control group. After successful induction of diabetes, in remaining three group, first group was given no treatment second group was treated with bromocriptine and the third group was treated with metformin. Fasting blood sugar of all the groups were measured on day 1, 7, 14 and 28 of treatment.

Results: In this study both the treatment groups were found to have significant (P<0.05) antihyperglycemic effect. Further studies are needed to evaluate and compare antihyperglycemic effect and safety profile of bromocriptine with established antidiabetic drugs.

Conclusions: From this study, we concluded that individually both metformin and bromocriptine were effective in controlling hyperglycemia but metformin was better in achieving normal mean FBS. Further studies are required to ascertain the consistency in hypoglycemic effect of bromocriptine as well as its effect in lipid profile and cardiovascular outcomes. Study taking different doses of bromocriptine or with increasing the duration of study can elaborate its role in achieving proper glycemic control over time.


Alloxan, Bromocriptine, Fasting blood sugar, Diabetes mellitus

Full Text:



Ashok Kumar CK. Oral hypoglycemic agents for treatment of type-ll diabetes mellitus: A review. 6(1):1.

Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathological approach. 6th ed. New York: McGraw-Hill Inc. 2005;1333.

Kyle JS. Candidates, a general overview of oral hypoglycemics for type 2 diabetes. Wyoming drug utilization review. 2008;22(4):25-35.

Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. International Diabetes Federation. 3rd ed. Belgium. International Diabetes Federation. 2006:15-103.

Sayers J. The world health report - Mental health: new understanding, new hope. Bulletin of the World Health Organization. 2001;79(11):1085.

Taylor DW. The Burden of Non-Communicable Diseases in India. Hamilton ON: The Cameron Institute. 2010:13.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217-30.

Ramachandran A. Epidemiology of diabetes in India: Three decades of research. J Assoc Physicians India. 2005;53:34-8.

Lawton C. Diabetes and aging: a growing concern. Perspectives. 1994;18(1):7-9.

Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol. 2009;41:197-8.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329(14):977-86.

Libman I, Arslanian S. Type 2 diabetes in childhood: The American perspective. Horm Res. 2003;59(1):69-76.

United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral anti-diabetic drugs in the United States, 1990- 2001. Diabetes Care. 2003;26:s1852-55.

Gerstein HC, Miller ME, Byington RP. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.

Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21-31.

DeFronzo RA. Banting lecture. From the triumvirate to the omnious octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-95.

De Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture. Diabetologia. 2010;53:1270-87.

Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AWK, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.

Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-6.

Defronzo RA. Bromocriptine. A sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-94.

Powers AC, D’Alessio D, Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia In: Brunton LL, editor, Goodman & Gillman’s The Pharmacological Basis of Therapeutics, 12th ed. New Delhi: McGraw Hill. 2011:1237-67.

Gaziano JM, Cincotta AH, O’Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized Clinical Trial of Quick-Release Bromocriptine among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes. Diabetes Care. 2010;33(7):1503-8.

Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes mellitus. BMJ. 1993;306:532-3.

Meier A, Cincotta A. Circadian rhythms regulates the expression of the thrifty genotype/phenotype. Diabetes Rev. 1996;4:464-87.

Cincotta A, Schiller B, Landry RJ, Herbert SJ, Miers W, Meier A. Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. Chronobiol Int. 1993;10:244-58.

Southern L, Cincotta A, Meier A, Binder T, Watkins

K. Bromocriptine induced reduction of body fat in pigs. J Anim Sci. 1990;68:931-6.

Erminio C, Greengard P. Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. In Advances in Biochemical Psychopharmacology. Goldstein M, Lieberman A, Calne D, Thorner M, editors. New York, Raven. 1980;23:41-62.

Luo S, Liang Y, Cincotta AH. Intracerebro ventricular administration of bromocriptine ameliorates the insulin resistant glucose intolerant state in hamsters. Neuroendocrinology. 1999;69:160-6.

Kamath V, Jones C, Yip J, Varasteh BB, Cincotta AH, Reaven GM, et al: Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697-701.

Meier A, Cincotta A, Lovell W: Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia. 1992;48:248-53.

Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.

Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Ind J Endocrinol Metab. 2011;15:S33-9.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V. A novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-61.

Das AK, Kalra S. Bromocriptine in diabetes management: Knowledge and attitudes of Indian physician. Int J Clin Cases Invest. 2011;2:5.

Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R. Guidelines for the diagnosis and treatment of hyperprolactinemia.J Reprod Med. 1999;44:1075-84.

Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of Parkinsonism with bromocriptine. Lancet. 1974;2:1355-6.